Alphabet

Company

Alphabet develops 4 assets, the furthest in phase 2 (ABBV-CLS-628 in autosomal dominant polycystic kidney disease). Mostly small molecule acting on proteostasis, EIF2B1 and EIF2B2.

4
Assets
Furthest stage: Phase 2; 2
Trials: 0
Signals

Pipeline

ABBV-CLS-628
Investigational drug for autosomal dominant polycystic kidney disease
Phase 2, Small molecule, autosomal dominant polycystic kidney disease
Fosigotifator
Activates eIF2B to decrease the integrated stress response.
Phase 2, Small molecule, Proteostasis, EIF2B1, vanishing white matter disease, ALS (Phase 1)
ABBV-CLS-484
Inhibits PTPN2 and PTPN1 for cancer immunotherapy.
Phase 1, locally advanced or metastatic tumors

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

Calico
4 assets, 2 trials

In the full profile

Evidence behind the mechanisms3
Trials2
Similar companies6

Papers

AI Driven Longevity Economics: Extending Dal Maso's Longevity Capitalism by the No-New-Actor Method, Chained Through the Research Horizon Gap and the Molecular Zero-Day to ALRP, and Stress-Tested Against the 2026 AI Bubble
Zenodo (CERN European Organization for Nuclear Research), 1 Jan 2026
THE DEBT THAT DOES NOT WAIT: Why Longevity's Race to the Bottom Outpaces AI's Own, and Why Three Named Actors Now Hold Both Ends of the Pipe
1 Jan 2026
NO NEW ACTOR TO NAME: Erman and Furendal's Market and Epistemic Authority, the Frontier AI Labs Now Funding Longevity Research, and Why the Dubai Longevity Authority Is Where the Question Stopped Being Speculative
1 Jan 2026